3rd Annual Pharmacovigilance 2012

3rd Annual Pharmacovigilance 2012

 

  • Early Bird Registration

    Sale Date Ended

    INR 4000
    Sold Out
  • Regular Registration

    Sale Date Ended

    INR 6000
    Sold Out
  • Group Discount

    Sale Date Ended

    INR 5000
    Sold Out
  • Bulk Booking

    Sale Date Ended

    INR 4000
    Sold Out

Invite friends

Contact Us

Page Views : 2498

About The Event

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

 

Conference Introduction:

After the successful journey of 1st and 2nd Annual Pharmacovigilance 2010 & 2011, Virtue Insight is proud to announce its 3rd Annual Pharmacovigilance 2012 in India. 

The Pharmaceutical industry in India is valued at Rs. 90,000 Crore and is growing at the rate of 12 – 14 % per annum. Exports are growing at 25 % Compound Annual Growth Rate (CAGR) every year. The total export of pharma products is to the extent of Rs. 40,000 Crore. India is now being recognized as the ‘Global pharmacy of Generic Drugs’ & has distinction of providing generic quality drugs at affordable cost. India is also emerging rapidly as a hub of Global Clinical trials & a destination for Drug Discovery & Development. Indian pharmaceutical industry is said to reach $20 billion by 2015, making it one of the world's top 10 pharmaceuticals markets. There is a surfeit of drug brands more than 6000 licensed drug manufactures and over 60,000 branded formulations. All medicines have potential risk as well as benefits. 

In 2011 India exported USD 10.3 billion worth of pharma products, registering 17.5 per cent growth over a year before. India's largest export destination for pharma products is still the USA, followed by the UK, Germany, South Africa and Russia. By 2020, the size of the global pharmaceutical market is anticipated to grow to USD 1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey 

The rapid induction in the market throws up the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base. All medicines (pharmaceuticals and vaccines) have side effects. Some of these side effects are known, while many are still unknown even though that medicine has been in clinical use for several years. It is important to monitor both the known and hitherto unknown side effects of medicines in order to determine any new information available in relation to their safety profile. In a vast country like India with a population of over 1.2 Billion with vast ethnic variability, different disease prevalence patterns, practice of different systems of medicines, different socioeconomic status, it is important to have a standardized and robust pharmacovigilance and drug safety monitoring programe for the nation.  Collecting this information in a systematic manner and analyzing the data to reach a meaningful conclusion on the continued use of these medicines. 

More clinical research activities being conducted in India, there is an immense need to understand the importance of pharmacovigilance and how it impacts the life cycle of the product. A good pharmacovigilance will easily identify the risk factors in the shortest time so that the harmful effects can be avoided or minimized. 

There are 2,000 deaths/year from unnecessary surgery; 7000 deaths/year from medication errors in hospitals; 20,000 deaths/year from other errors in hospitals; 80,000 deaths/year from infections in hospitals; 106,000 deaths/year from non-error, adverse effects of medications - these total up to 225,000 deaths per year in the US. Based on the findings of one major study, medical errors kill some 44,000 people in U.S. hospitals each year. Another study puts the number much higher, at 98,000. Even using the lower estimate, more people die from medical mistakes each year than from highway accidents, breast cancer, or AIDS. And deaths from medication errors that take place both in and out of hospitals are aid to be more than 7,000 annually. 

Pharmacovigilance 2012 will discuss the pressing concerns confronted with regard to drug safety, addressing the risks, time line, budget constrains, effectively tackling key challenges, overcoming trial agreement and site contract negotiation hurdles. Top pharmaceutical, biotech, and regulatory representatives will discuss the current complexities and controversies in pharmacovigilance and risk management throughout all phases of development 

The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.  The entire program will cover the detection, analysis and prevention of adverse drug reactions.  It will be studied with the help of case studies and industry experiences. 

Pharmacovigilance 2012 is the latest in Virtue Insight’s series of successful pharmacovigilance events. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, 3rd Annual Pharmacovigilance 2012 will provide an important platform for pharmacovigilance stakeholders from India to discuss and share best practices in expediting pharmacovigilance development in India. 

It gives me great pleasure in welcoming all of you to the virtue insight’s 3rd Annual Pharmacovigilance 2012.  I wish and pray that all our efforts will be beneficial to our industries and to our country at large.

Key Themes Discussed at this Conference:

  • Exploiting the latest technologies, methodologies and Introducing pharmacy automations on work practices of Pharmacovigilance
  • Keeping abreast of the changes impacting the drug safety industry to ensure the pharmacovigilance strategies are robust and geared to compliance
  • Recent successful strategies and business models to bring out new medicines
  • How will PV activities change with Clinical Trial Transformation Initiative?
  • Identifying essential antidote requirements and learn to implement best practices in drug safety and surveillance
  • Exploiting the pharmacy automations and technologies for enhancement of medication safety
  • Stay ahead of computing and electronic communications in pharmacovigilance
  • Latest developments in pharmacovigilance, drug safety and risk management to ensure safer drugs to market
  • Establishing the importance of pharmacovigilance for the safety of the patient
  • Determining the steps and strategies for enhancing quality in healthcare
  • Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
  • Analyzing the information on current industry projects and trends
  • Identifying the latest regulatory framework for pharmacovigilance
  • Global marketing strategies in order to engage with regulatory centers of excellence on pharmacovigilance
  • Accelerating new medicine introduction in developing world & overcoming challenges
  • Explaining how to use the data sources and observational research for effective safety analysis
  • Good supply chain management practices for medicine distribution
  • Be part of a major networking opportunity

Key Speakers:

  • Bhaswat S. Chakraborty, Senior VP & Chair, Research and Development, Cadila
  • Arun Bhatt, President, Clininvent Research
  • Vinod Mattoo, Medical Director, Metabolic Disease Strategy, Asia-Pacific, Bristol-Myers Squibb (Singapore)
  • D.K. Chauhan, ADCI, CDSCO - Mumbai Port, (Central Drug Standard Control Organisation) 
  • SK Gupta, Professor Emeritus and Head, Clinical Research, DIPSAR (University of Delhi) & Advisor To Pharmacovigilance Program of India (PvPI)
  • Dilip Pawar, Director and Head - Clinical Development, Dr Reddys
  • Babita Kirodian, Head - Country Pharmacovigilance, Bristol Myers Squibb
  • Hari Prasad, CEO, Apollo Hospitals
  • Rajani Rokade, Head - Pharmacovigilance, Sanofi Aventis
  • Manish R Garg, Country Medical Director India, Bayer
  • Siddarth Chachad, Head - Medical Services, Cipla
  • Deepti Sanghavi, Senior Medical Writer, SiroClinPharm
  • Indu Nambiar, Clinical Safety Officer(CSO), Boehringer Ingelheim
  • Simrat Sohal, Clinical Research Physician - Patient safety and Critical care, Eli Lilly
  • Milind Antani, Head - Pharma LifeSciences group, Nishith Desai Associates

And many more...

Who should attend:

VP’s, Directors, CRO’s, Heads and Managers of: 

  • Pharmacovigilance Strategy
  • Drug Safety/Risk Management
  • Information and Clinical Data Management
  • Clinical Research
  • Research & Development
  • Product Safety/Assurance Assessment
  • Patient Safety & Outcomes Research & Data Analysis
  • Epidemiology project management
  • Regulatory Affairs and Compliance
  • Sales & Marketing
  • Biotech manufacturers

Why should you attend:

3rd Annual Pharmacovigilance 2012- “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management ”

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.

Venue Map